🏆 Deal of the Week · CW 20/2026
Isomorphic Labs raised USD 2.1 billion in a Series B round; the company has not disclosed its post-money valuation. The round was led by Thrive Capital. Proceeds are earmarked to scale the company's AI-driven drug design engine and expand its computational life sciences capabilities.
Isomorphic Labs — key deal facts
| Company | Isomorphic Labs |
| Founded | 2021 |
| Headquarters | London, United Kingdom |
| Amount raised | USD 2.1b |
| Valuation | Valuation Remains Undisclosed |
| Round | Series B |
| Investors | The round was led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund |
| Sectors | AI, BioTech, Pharmaceutical |
Who invested in Isomorphic Labs?
The round was led by Thrive Capital and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. The investor syndicate is notable for combining a leading US growth-equity firm with Isomorphic Labs' parent-company backer Alphabet, two sovereign wealth vehicles — Abu Dhabi's MGX and Singapore's Temasek — and direct backing from the UK government through its Sovereign AI Fund. That breadth of institutional support reflects cross-border conviction in AI-enabled drug discovery as a strategic asset class.
What does Isomorphic Labs do?
Isomorphic Labs is an AI drug discovery company founded on 24 February 2021 by Demis Hassabis, co-founder of DeepMind, and headquartered in London, United Kingdom. The company operates as an Alphabet subsidiary, spun out of DeepMind to commercialise its computational biology research. Its core product is an AI drug design engine that unifies search-based and generative AI models — built on the foundation of DeepMind's Nobel Prize-winning AlphaFold protein-structure system — and runs on Google Cloud infrastructure to accelerate molecular design and drug performance prediction at scale. Isomorphic Labs sits at the intersection of artificial intelligence, biotechnology, and pharmaceuticals, with the stated goal of compressing the timeline and cost of bringing novel therapeutics to patients.
Isomorphic Labs valuation & multiples
Isomorphic Labs operates at the intersection of biotechnology, artificial intelligence, and pharmaceuticals, with a focus on accelerating drug discovery through advanced AI models and computational life sciences research. European benchmarks for AI-enabled biotechnology and pharmaceutical businesses (Q1 2026) indicate EV/Sales multiples of 3.61x–4.99x and EV/EBITDA multiples of 16.84x–20.68x at the Series B stage. Investors seeking a deeper view of comparable transaction pricing can explore Venionaire DealMatrix's AI, BioTech, and Pharmaceutical sector multiples pages.
Explore the benchmarks: Series B Pharmaceutical.
Frequently asked questions
How much did Isomorphic Labs raise in its Series B?
Isomorphic Labs raised USD 2.1 billion in its Series B round, announced in 2025.
What is Isomorphic Labs's valuation?
Isomorphic Labs's post-money valuation has not been disclosed.
Who invested in Isomorphic Labs?
The Series B was led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
When was Isomorphic Labs founded and where is it based?
Isomorphic Labs was founded on 24 February 2021 and is headquartered in London, United Kingdom.
Source: original announcement — read the full report.